Skip to main content

Table 3 Immunology response of patients \( \left(\overline{x}\pm \mathrm{s}\right) \)

From: Feasibility study of DCs/CIKs combined with thoracic radiotherapy for patients with locally advanced or metastatic non-small-cell lung cancer

Group CD3+(%) CD3+CD4+(%) CD3+CD8+(%) CD4+/CD8+ CD3CD56+(%) IL-2 (ng/L) IFN-r (pg/mL)
Treatment group        
 Pre-treatment 62.16 ± 13.62 33.64 ± 10.05 25.86 ± 10.30 1.55 ± 0.88 17.83 ± 9.04 330.42 ± 79.25 575.85 ± 179.85
 Post-treatment 66.34 ± 13.65 34.63 ± 13.28 29.73 ± 11.14 1.45 ± 0.97 17.31 ± 9.50 330.94 ± 66.12 567.12 ± 151.64
 P value 0.3 0.716 0.119 0.684 0.806 0.979 0.831
Control group        
 Pre-treatment 68.70 ± 15.48 39.48 ± 12.76 27.30 ± 8.79 1.57 ± 0.67 10.25 ± 6.12 358.37 ± 49.00 491.19 ± 60.00
 Post-treatment 70.43 ± 19.67 33.6471 ± 18.02 33.65 ± 17.19 1.27 ± 0.96 8.52 ± 6.52 376.09 ± 44.44 507.32 ± 59.87
 P value 0.705 0.051 0.077 0.08 0.378 0.186 0.481